Comparison of the Effectiveness of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients with Parkinson's Disease

Overview

Journal Curr J Neurol

Publisher Tehran University of Medical Sciences

Specialty Neurology

Date 2024 Oct 21

PMID 39431232

Authors

Ahmad Chitsaz

Mohammad Reza Najafi

Farzaneh Habibi

Sajad Amirhajloo

Affiliations

Soon will be listed here.

Abstract

A large percentage of patients with Parkinson's disease (PD) suffer from excessive daytime sleepiness (EDS). This study aims to compare the effectiveness of modafinil and methylphenidate on EDS and side effects. Fifty nine patients with PD and EDS [Epworth Sleepiness Scale (ESS) more than 9] were recruited in a double-blind placebo controlled trial. Twenty-two patients received modafinil 200 mg daily, twenty-six patients received methylphenidate 10 mg daily, and 11 patients received placebo for 6 weeks. Pittsburgh Sleep Quality Index (PSQI) and ESS were filled out at baseline and 6 weeks later. There was no significant difference in demographics, PSQI, and ESS variables at baseline. The mean of ESS scores decreased significantly in modafinil (17.36 ± 5.05 vs. 10.55 ± 4.62, P 0.001 and methylphenidate (16.27 ± 5.40 vs. 12.23 ± 6.28, P < 0.001) groups after 6-week trial, compared with control group (14.27 ± 4.49 vs. 14.09 ± 4.46, P = 0.710). The effectiveness of modafinil and methylphenidate on improving daytime sleepiness and night sleep of patients was not significantly different. Both modafinil and methylphenidate were effective drugs in improving EDS and quality of sleep without significant difference in efficiency and side effects.

References

Shen Y, Huang J, Li J, Liu C . Excessive Daytime Sleepiness in Parkinson's Disease: Clinical Implications and Management. Chin Med J (Engl). 2018; 131(8):974-981. PMC: 5912065. DOI: 10.4103/0366-6999.229889. View

Dauvilliers Y, Roth T, Guinta D, Alvarez-Horine S, Dynin E, Black J . Effect of sodium oxybate, modafinil, and their combination on disrupted nighttime sleep in narcolepsy. Sleep Med. 2017; 40:53-57. DOI: 10.1016/j.sleep.2017.07.030. View

Mitler M, Shafor R, Hajdukovich R, Timms R, Browman C . Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep. 1986; 9(1 Pt 2):260-4. DOI: 10.1093/sleep/9.1.260. View

Sobreira-Neto M, Pena-Pereira M, Tavares Sobreira E, Chagas M, Fernandes R, Tumas V . High Frequency of Sleep Disorders in Parkinson's Disease and Its Relationship with Quality of Life. Eur Neurol. 2017; 78(5-6):330-337. DOI: 10.1159/000481939. View

Bosco A, Lopez R, Barateau L, Chenini S, Pesenti C, Pepin J . Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy. Neurology. 2018; 90(6):e479-e491. DOI: 10.1212/WNL.0000000000004911. View

Battleday R, Brem A . Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review. Eur Neuropsychopharmacol. 2015; 25(11):1865-81. DOI: 10.1016/j.euroneuro.2015.07.028. View

Leonard B, McCartan D, White J, King D . Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol. 2004; 19(3):151-80. DOI: 10.1002/hup.579. View

Loddo G, Calandra-Buonaura G, Sambati L, Giannini G, Cecere A, Cortelli P . The Treatment of Sleep Disorders in Parkinson's Disease: From Research to Clinical Practice. Front Neurol. 2017; 8:42. PMC: 5311042. DOI: 10.3389/fneur.2017.00042. View

Saletu B, Frey R, Krupka M, Anderer P, Grunberger J, Barbanoj M . Differential effects of a new central adrenergic agonist--modafinil--and D-amphetamine on sleep and early morning behaviour in young healthy volunteers. Int J Clin Pharmacol Res. 1989; 9(3):183-95. View

10.

Sobanski E, Schredl M, Kettler N, Alm B . Sleep in adults with attention deficit hyperactivity disorder (ADHD) before and during treatment with methylphenidate: a controlled polysomnographic study. Sleep. 2008; 31(3):375-81. PMC: 2276739. DOI: 10.1093/sleep/31.3.375. View

11.

Banerjee D, Vitiello M, Grunstein R . Pharmacotherapy for excessive daytime sleepiness. Sleep Med Rev. 2004; 8(5):339-54. DOI: 10.1016/j.smrv.2004.03.002. View

12.

Billiard M, Besset A, Montplaisir J, Laffont F, Goldenberg F, WEILL J . Modafinil: a double-blind multicentric study. Sleep. 1994; 17(8 Suppl):S107-12. DOI: 10.1093/sleep/17.suppl_8.s107. View

13.

Rodrigues T, Caldas A, Ferreira J . Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson's disease: Systematic review and meta-analysis. Parkinsonism Relat Disord. 2016; 27:25-34. DOI: 10.1016/j.parkreldis.2016.03.002. View

14.

Devos D, Krystkowiak P, Clement F, Dujardin K, Cottencin O, Waucquier N . Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 2006; 78(5):470-5. PMC: 2117830. DOI: 10.1136/jnnp.2006.100016. View

15.

Black J, Swick T, Bogan R, Lai C, Carter L . Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy. Sleep Med. 2016; 24:57-62. DOI: 10.1016/j.sleep.2016.07.010. View

16.

Thorpy M, Schwartz J, Kovacevic-Ristanovic R, Hayduk R . Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label safety study assessing three strategies. Psychopharmacology (Berl). 2003; 167(4):380-5. DOI: 10.1007/s00213-002-1343-4. View

17.

Nieves A, Lang A . Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol. 2002; 25(2):111-4. DOI: 10.1097/00002826-200203000-00010. View

18.

Falup-Pecurariu C, Diaconu S . Sleep Dysfunction in Parkinson's Disease. Int Rev Neurobiol. 2017; 133:719-742. DOI: 10.1016/bs.irn.2017.05.033. View

19.

Challman T, Lipsky J . Methylphenidate: its pharmacology and uses. Mayo Clin Proc. 2000; 75(7):711-21. DOI: 10.4065/75.7.711. View

20.

Sheikhina N, Najafi M, Chitsaz A, Ghadimi K . Evaluation of the effectiveness of methylphenidate and modafinil in the treatment of daily drowsiness in patients with refractory epilepsy and their comparison with the control group. Am J Neurodegener Dis. 2021; 10(5):69-75. PMC: 8610805. View